Vaxcyte launches $1 billion equity and convertible‑note offering
Vaxcyte Inc. announced concurrent public offerings of $500 million of common stock (including pre‑funded warrants) and $500 million of 1.5% senior convertible notes due 2032. The equity tranche consists of 7,412,500 shares at $64 each with a 30‑day over‑allotment option for an additional 1,171,875 shares, while the note tranche carries a conversion price of $89.60 per share and a 30‑day option for up to $75 million more principal. Proceeds are earmarked for clinical development of the VAX‑31 vaccine program, manufacturing scale‑up and related corporate purposes. The offerings are expected to close on October 9, 2026, subject to customary conditions.
Why it matters
The company expects the roughly $1 billion net of fees to fund Phase 3 adult and infant VAX‑31 trials, expand manufacturing capacity and prepare for a U.S. launch, extending its cash runway. The equity component will dilute existing shareholders, while the convertible notes add debt that can convert into equity at a 40% premium to the offering price, potentially increasing future dilution.
Key facts
- 1Vaxcyte offered 7,412,500 shares of common stock at $64.00 per share. globenewswire.com
- 2The equity offering includes 400,000 pre‑funded warrants priced at $63.999 each with an exercise price of $0.001 per share. globenewswire.com
- 3Underwriters have a 30‑day option to purchase up to an additional 1,171,875 shares of common stock. globenewswire.com
- 4The note offering totals $500 million principal amount of 1.50% convertible senior notes due October 15, 2032. globenewswire.com
- 5Note underwriters have a 30‑day option to purchase up to $75 million additional principal. globenewswire.com
- 6Notes initially convert at an implied price of $89.60 per share, a 40% premium to the $64 offering price. globenewswire.com
Summary written by AlphAI from 15 of 15 sources. Not investment advice. Figures are as stated by the linked sources.